Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 9/20 | 0.39 |
| ▸ | SLC9A3 | P48764 | 4/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493264 | 0.86 | MEN1 (0.32) | SLC9A3MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL492844 | 0.86 | PTGIR (0.40) | PTGIRSLC9A3FAAHACHEBCHE | |
| SCHEMBL493515 | 0.84 | AVPR1B (0.37) | PTGIRFAAHACHEBCHEMEN1 | |
| SCHEMBL493109 | 0.80 | SLC9A3 (0.35) | PTGIRSLC9A3ALDH1A1 | |
| SCHEMBL493160 | 0.79 | PTGIR (0.36) | PTGIRSLC9A3MEN1KMT2A | |
| SCHEMBL493901 | 0.79 | PTGIR (0.41) | PTGIRMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL493623 | 0.79 | PTGIR (0.40) | PTGIRFAAHACHEBCHEMEN1 | |
| SCHEMBL493506 | 0.78 | PTGIR (0.35) | PTGIRSLC9A3KMT2AHPGD | |
| SCHEMBL494153 | 0.78 | PTGIR (0.35) | PTGIRSLC9A3 | |
| SCHEMBL492721 | 0.78 | CXCR3 (0.43) | PTGIRFAAHACHEBCHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | PTGIR 121/4885SLC9A3 2717/4885FAAH 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.